Search results
Showing 16 to 20 of 20 results for nintedanib cancer- non-small cell lung cancer
In development Reference number: GID-TA11277 Expected publication date: TBC
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Discontinued Reference number: GID-TA11289
Targeted treatment for rare form of aggressive lung cancer gets NICE approval
Mobocertinib recommended as a treatment for a rare and aggressive form of lung cancer